MX2021008560A - Methods of treating tyrosine kinase inhibitor-induced diarrhea. - Google Patents

Methods of treating tyrosine kinase inhibitor-induced diarrhea.

Info

Publication number
MX2021008560A
MX2021008560A MX2021008560A MX2021008560A MX2021008560A MX 2021008560 A MX2021008560 A MX 2021008560A MX 2021008560 A MX2021008560 A MX 2021008560A MX 2021008560 A MX2021008560 A MX 2021008560A MX 2021008560 A MX2021008560 A MX 2021008560A
Authority
MX
Mexico
Prior art keywords
methods
tyrosine kinase
kinase inhibitor
induced diarrhea
treating tyrosine
Prior art date
Application number
MX2021008560A
Other languages
Spanish (es)
Inventor
Alan S Verkman
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2021008560A publication Critical patent/MX2021008560A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles

Abstract

The disclosure is directed to methods of treating tyrosine kinase inhibitor-induced diarrhea by administering a potassium channel inhibitor, or a CFTR chloride channel inhibitor, or a combination thereof.
MX2021008560A 2019-01-16 2020-01-16 Methods of treating tyrosine kinase inhibitor-induced diarrhea. MX2021008560A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962793291P 2019-01-16 2019-01-16
PCT/US2020/013941 WO2020150517A2 (en) 2019-01-16 2020-01-16 Methods of treating tyrosine kinase inhibitor-induced diarrhea

Publications (1)

Publication Number Publication Date
MX2021008560A true MX2021008560A (en) 2021-09-21

Family

ID=69724055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008560A MX2021008560A (en) 2019-01-16 2020-01-16 Methods of treating tyrosine kinase inhibitor-induced diarrhea.

Country Status (12)

Country Link
US (1) US20220088026A1 (en)
EP (1) EP3911308A2 (en)
JP (1) JP2022518428A (en)
KR (1) KR20210119425A (en)
CN (1) CN113301921A (en)
AU (1) AU2020208452A1 (en)
BR (1) BR112021014043A2 (en)
CA (1) CA3126401A1 (en)
IL (1) IL284857A (en)
MX (1) MX2021008560A (en)
TW (1) TW202042799A (en)
WO (1) WO2020150517A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022047289A1 (en) * 2020-08-28 2022-03-03 Emory University Methods of managing cocaine or other drug addictions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889038A (en) * 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
US20020004519A1 (en) * 1998-09-23 2002-01-10 Wayne I. Lencer Method for reducing chloride secetion by intestinal epithlial cells in situ

Also Published As

Publication number Publication date
WO2020150517A3 (en) 2020-11-26
CN113301921A (en) 2021-08-24
JP2022518428A (en) 2022-03-15
IL284857A (en) 2021-08-31
WO2020150517A2 (en) 2020-07-23
TW202042799A (en) 2020-12-01
BR112021014043A2 (en) 2021-09-21
EP3911308A2 (en) 2021-11-24
CA3126401A1 (en) 2020-07-23
KR20210119425A (en) 2021-10-05
US20220088026A1 (en) 2022-03-24
AU2020208452A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
MX2021007576A (en) Novel anti-ccr8 antibody.
MX2021014441A (en) Tead inhibitors and uses thereof.
MX2021014443A (en) Tead inhibitors and uses thereof.
EP4302835A3 (en) Methods of treating ovarian cancer
CR20220354A (en) Inhibitors of mutant forms of egfr
PH12020500655A1 (en) Compounds
MX2021007773A (en) Egfr inhibitor compounds.
CR20200228A (en) COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION (Divisional 2016-0554)
EA201991580A1 (en) PYRIMIDINE COMPOUND AND ITS PHARMACEUTICAL USE
MX2021016049A (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer.
PH12021550558A1 (en) Modulators of pnpla3 expression
MX2018012797A (en) Erbb inhibitors and uses thereof.
EA202191086A1 (en) COMBINED MELANOMA THERAPY
PH12019502174A1 (en) Modulators of pcsk9 expression
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
MY193239A (en) Novel b-lactamase inhibitors
MY189557A (en) Pyridone compound as c-met inhibitor
MX2021015514A (en) Heterocyclic compound.
MX2021008560A (en) Methods of treating tyrosine kinase inhibitor-induced diarrhea.
PH12019500479A1 (en) Compositions for treating dementia
MX2022014126A (en) Enpp1 modulators and uses thereof.
WO2018166993A3 (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
MX2022004270A (en) Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency.
MX2022006750A (en) Masp-2 inhibitors and methods of use.
WO2020055544A3 (en) Method for treating pancreatic cancer